The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
dc.contributor.author | Evens, Andrew | |
dc.contributor.author | Hong, Fangxin | |
dc.contributor.author | Gordon, Leo I. | |
dc.contributor.author | Fisher, Richard I. | |
dc.contributor.author | Bartlett, Nancy L. | |
dc.contributor.author | Connors, Joseph M. | |
dc.contributor.author | Gascoyne, Randy D. | |
dc.contributor.author | Wagner, Henry | |
dc.contributor.author | Gospodarowicz, Mary | |
dc.contributor.author | Cheson, Bruce D. | |
dc.contributor.author | Stiff, Patrick J. | |
dc.contributor.author | Advani, Ranjana | |
dc.contributor.author | Miller, Thomas P. | |
dc.contributor.author | Hoppe, Richard T. | |
dc.contributor.author | Kahl, Brad S. | |
dc.contributor.author | Horning, Sandra J. | |
dc.date | 2022-08-11T08:08:19.000 | |
dc.date.accessioned | 2022-08-23T15:51:04Z | |
dc.date.available | 2022-08-23T15:51:04Z | |
dc.date.issued | 2013-04-01 | |
dc.date.submitted | 2013-07-02 | |
dc.identifier.citation | Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29. <a href="http://dx.doi.org/10.1111/bjh.12222">Link to article on publisher's site</a> | |
dc.identifier.issn | 0007-1048 (Linking) | |
dc.identifier.doi | 10.1111/bjh.12222 | |
dc.identifier.pmid | 23356491 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/28810 | |
dc.description.abstract | There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) and Stanford V (SV; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone) regimens in older Hodgkin lymphoma (HL) patients. Forty-four advanced-stage, older HL patients (aged >/=60 years) were treated on the randomized study, E2496. Toxicities were mostly similar between chemotherapy regimens, although 24% of older patients developed bleomycin lung toxicity (BLT), which occurred mainly with ABVD (91%). Further, the BLT-related mortality rate was 18%. The overall treatment-related mortality for older HL patients was 9% vs. 0.3% for patients aged (P < 0.001). Among older patients, there were no survival differences between ABVD and SV. According to age, outcomes were significantly inferior for older versus younger patients (5-year failure-free survival: 48% vs. 74%, respectively, P = 0.002; 5-year overall survival: 58% and 90%, respectively, P < 0.0001), although time-to-progression (TTP) was not significantly different (5-year TTP: 68% vs. 78%, respectively, P = 0.37). Furthermore, considering progression and death without progression as competing risks, the risk of progression was not different between older and younger HL patients (5 years: 30% and 23%, respectively, P = 0.30); however, the incidence of death without progression was significantly increased for older HL patients (22% vs. 9%, respectively, P < 0.0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23356491&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | http://dx.doi.org/10.1111/bjh.12222 | |
dc.subject | Age Factors | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | effects | |
dc.subject | Bleomycin | |
dc.subject | Dacarbazine | |
dc.subject | Doxorubicin | |
dc.subject | Etoposide | |
dc.subject | Female | |
dc.subject | Hematologic Diseases | |
dc.subject | Hodgkin Disease | |
dc.subject | Humans | |
dc.subject | Lung Diseases | |
dc.subject | Male | |
dc.subject | Mechlorethamine | |
dc.subject | Middle Aged | |
dc.subject | Neoplasm Staging | |
dc.subject | Prednisone | |
dc.subject | Survival Analysis | |
dc.subject | Treatment Outcome | |
dc.subject | Vinblastine | |
dc.subject | Vincristine | |
dc.subject | Clinical Epidemiology | |
dc.subject | Hematology | |
dc.subject | Hemic and Lymphatic Diseases | |
dc.subject | Oncology | |
dc.title | The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 | |
dc.type | Journal Article | |
dc.source.journaltitle | British journal of haematology | |
dc.source.volume | 161 | |
dc.source.issue | 1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/faculty_pubs/105 | |
dc.identifier.contextkey | 4276321 | |
html.description.abstract | <p>There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) and Stanford V (SV; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone) regimens in older Hodgkin lymphoma (HL) patients. Forty-four advanced-stage, older HL patients (aged >/=60 years) were treated on the randomized study, E2496. Toxicities were mostly similar between chemotherapy regimens, although 24% of older patients developed bleomycin lung toxicity (BLT), which occurred mainly with ABVD (91%). Further, the BLT-related mortality rate was 18%. The overall treatment-related mortality for older HL patients was 9% vs. 0.3% for patients aged (P < 0.001). Among older patients, there were no survival differences between ABVD and SV. According to age, outcomes were significantly inferior for older versus younger patients (5-year failure-free survival: 48% vs. 74%, respectively, P = 0.002; 5-year overall survival: 58% and 90%, respectively, P < 0.0001), although time-to-progression (TTP) was not significantly different (5-year TTP: 68% vs. 78%, respectively, P = 0.37). Furthermore, considering progression and death without progression as competing risks, the risk of progression was not different between older and younger HL patients (5 years: 30% and 23%, respectively, P = 0.30); however, the incidence of death without progression was significantly increased for older HL patients (22% vs. 9%, respectively, P < 0.0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events.</p> | |
dc.identifier.submissionpath | faculty_pubs/105 | |
dc.contributor.department | Department of Medicine, Division of Hematology/Oncology | |
dc.source.pages | 76-86 |